The International Hip Dysplasia Registry aims to address gaps in evidence demonstrated by the 2014 AAOS guidelines, with the goal of identifying the best practices, standardizing treatment and management, and optimizing clinical and functional outcomes for children with DDH. With international collaborations already established from the IHDI study group, the prospective registry collects data on all infants referred for DDH screening across a vast array of geographic locations (16 confirmed centres in five countries across four continents).
This registry is the largest of its kind, in size and scope, to study the full spectrum of hip dysplasia over time during treatment as well as the multi-centre assessment of various forms of treatment for otherwise healthy infants and children with hip dysplasia. The target population is all infants and children diagnosed with any form of DDH from birth up to 10 years of age. Capturing the breadth of diagnoses within the DDH spectrum provides a unique and unprecedented platform for examining numerous aspects of the full DDH spectrum, including treatment outcomes and risk factors in both the short and long term.
Considering universal clinical screening efforts and the abundance of routine or selective ultrasound screening programs, improvements to this process will directly impact not only hundreds of thousands of children and their families worldwide, but also provide cost and resource savings for hospitals and medical systems.
There is enormous potential to be able to tangibly change current screening practices and monitoring protocols within the next 2-3 years. In the longer term, we aim to identify prognostic factors and best treatment practices to improve outcomes for children around the world. This will not only have an actionable impact on the estimated 220,000-308,000 infants who are screened for DDH risk factors each year in North America alone, but also save on economic and social costs to both the families and hospital/health care systems.